Biography
Vik is a seasoned litigator with a deep focus on intellectual property (IP) enforcement and litigation, particularly for leading companies and trade associations in the technology and software sectors including Microsoft Corporation, Adobe Systems Inc., Autodesk Inc., and the Business Software Alliance (BSA).
Vik’s practice encompasses a wide range of IP disputes, from complex contractual and licensing issues, to copyright and trademark litigation. His experience and expertise allows him to safeguard his clients’ most valuable assets with precision and efficiency.
Beyond his work in technology, Vik also has considerable experience in pharmaceutical patent litigation and has most recently also represented clients in several high-profile oil and gas patent litigation cases.
Vik’s extensive courtroom experience spans both the Federal Court and the Federal Court of Appeal, where he has successfully handled a diverse array of high-stakes cases.
Academically, Vik consistently excelled, graduating in 2001 with Honours from both McGill University (B.Sc.) and then Osgoode Hall Law School (J.D.). He has received numerous academic accolades, and, at just 21, earned distinction as one of the youngest first-authors of an international peer-reviewed publication in Protein Science.
Outside of his legal practice, Vik is an avid polyglot and traveler with a passion for exploring the world—having visited over 45 countries—and enjoys activities such as surfing, hiking, and, on occasion, surviving plane crashes.
*Practicing as Tenekjian Professional Corporation
Representative Cases
- Steelhead LNG (ASLNG) Ltd. v. Arc Resources Ltd., 2024 FCA 67
- Steelhead LNG (ASLNG) Ltd. v. ARC Resources Ltd., 2023 FC 1684
- Steelhead LNG (ASLNG) Ltd. v. ARC Resources Ltd., 2022 FC 998
- Microsoft Corporation v. Liu, 2016 FC 950
- AstraZeneca Canada Inc. v. Apotex Inc., 2013 FCA 47
- AstraZeneca Canada Inc. v. Ranbaxy Pharmaceuticals Canada Inc., 2013 FC 232
- Adobe Systems Incorporated et al v. Dale Thompson, 2012 FC 1219
- AstraZeneca Canada Inc. v. Pharmascience Inc., 2012 FC 1189
- AstraZeneca Canada Inc v. Apotex Inc, 2012 FC 991
- AstraZeneca Canada Inc. and AstraZeneca AB v. Mylan Pharmaceuticals ULC and Minister of Health, T-134-10 (Federal Court), April 2010 (unpublished)
- Abbott Laboratories Ltd. v. Canada (Health), 2008 FC 919
- AstraZeneca Canada Inc. v. Apotex Inc., 2008 FC 537
- Abbott Laboratories Ltd. v. Canada (Health), 2007 FC 865
- Novopharm Ltd. v. Abbott Laboratories Ltd., 2007 FCA 251
- Eli Lilly Canada Inc. v. Novopharm Ltd., 2006 FC 1278
- Calgon Carbon Corporation v. North Bay (City), 2006 FC 1373
Publications
- “Immunochemical evidence that cholesteryl ester transfer protein and bactericidal/permeability-increasing protein share a similar tertiary structure,” Protein Science, 8, pp. 2392-2398, doi:10.1110/ps.8.11.2392, 1999.
- “The Same But Different: Patent Linkage in Canada”, LMG Life Sciences, 2, p. 153.